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Short Term Effects of Electronic Cigarettes on Pulmonary Function in
Healthy Adult Smokers When Compared to Conventional Cigarette Use
Kayleen Lynch and Rachel Bastianelli

Abstract
Background: Electronic cigarettes (e-cigarettes) first appeared on the U.S. market in 20071, but
to date, little is known about their safety. Concern about long term adverse effects on overall
health continues to increase as we explore the potential of e-cigarettes to aid in smoking
cessation practices. E-cigarettes have gained popularity and support through this idea that by
using them to help patients quit smoking, the benefits of ultimately abstaining from tobacco use
will outweigh the harms associated with e-cigarette use1. While the idea of reducing tobacco
usage by any means possible remains the goal for most providers, without clear-cut
recommendations from the Food and Drug Administration (FDA) and Centers for Disease
Control (CDC) and supportive long term research and data analysis, providers are being forced
to decide between the lesser of two evils. Objective: The purpose of this review is to explore
current research that quantifiably measures the effect of e-cigarettes on pulmonary function.
Methods: A PubMed search was performed using the MeSH terms “electronic nicotine delivery
systems” or “vaping,” and “respiratory function tests,” and a Scopus search was performed
using the terms “respiratory function test,” “electronic cigarette,” and “short-term.” Search
results were then further stratified to exclude articles with non-human species (3 articles), nonhealthy subjects (4 articles), review articles (2 articles), and non-smokers (5 articles). Of the
articles remaining, one article was excluded for being a single subject case study, and the rest
were used for quantitative meta-analysis. Conclusion: The results of the 3 studies included in the
meta-analysis revealed a lack of statistically significant changes in pulmonary function as
demonstrated by FEV1 and FVC with the use of e-cigarettes vs. conventional cigarettes. Further
well-designed long-term RCT’s are needed in order to elicit more conclusive evidence on the
safety of e-cigarettes before formal recommendations can be made to patients regarding their
use.
Keywords: Electronic cigarette (e-cigarette), electronic nicotine delivery devices (ENDS), The Food and
Drug Administration (FDA), The Centers for Disease Control (CDC), pulmonary function tests (PFTs),
chronic obstructive pulmonary disease (COPD), forced vital capacity (FVC), peak expiratory flow (PEF),
forced expiratory volume in 1 second (FEV1), Tiffeneau-Pinelli index (FEV1/FVC), blood pressure (BP),
heart rate (HR), carbon monoxide (CO), nitrous oxide (NO), dynamic inhalation scintigraphy (DIS)
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Introduction
To date, little is known about the safety of e-cigarettes, and with a recent nationwide
outbreak of severe respiratory illness associated with use of e-cigarettes or vaping products, there
is increasing concern for public safety. The general public is under the invalid assumption that ecigarettes are harmless or that they impose a lower overall health risk compared to that brought
on by conventional cigarette use1. Appealing to the public through this idea of “harm reduction”
masks the lack of credible research surrounding this topic1.

A typical e-cigarette is composed of three main components including a rechargeable or
disposable battery, a heating element that generates an inhalable aerosol, and either a switch or
puff-activated circuitry2. The typical commercial e-cigarette also has a liquid solution containing
aerosol-forming excipients such as glycerol and/or propylene glycol, flavoring materials and
optionally, nicotine2. According to the surgeon general, e-cigarettes can contain other potentially
harmful chemicals including flavorants such as diacetyl, a chemical linked to serious lung
disease, volatile organic compounds, and heavy metals such as nickel, tin, and lead3.

The liquid solution within the e-cigarette is usually delivered from a small reservoir by
capillary wicking to the heating zone, which generates an aerosol resembling cigarette smoke2.
The devices have many different names such as vape pens, pod mods, tanks, ENDS, e-hookahs
and e-cigarettes4. The liquid contained within may be called e-juice, e-liquid, cartridges, pods, or
oil4. A large variety of e-cigarette sizes, configurations, formulations, and designs are emerging
on a continual basis in response to an expanding worldwide marketplace and evolving personal
preferences2.
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Concern about long term adverse effects of e-cigarettes on overall health continues to
grow as we explore their potential to aid in smoking cessation practices. E-cigarette use first
appeared on the U.S. market in 20071. Since then both experimental and regular use has become
increasingly popular amongst various age groups within the population. The rationale behind
choosing an e-cigarette over a conventional cigarette varies amongst users. A global survey of ecigarette users revealed that the majority of middle-aged and older adults who currently smoke or
previously smoked conventional cigarettes reported using e-cigarette as a means to quit smoking
conventional cigarettes and improve their overall health1.

Over the last ten years, the association between increased e-cigarette use and overall
smoking cessation rates has become apparent and is commonly brought up in conversations with
healthcare providers in a primary care setting1. Clinical research has shown a correlation between
smoking and poor health outcomes. Cessation is considered one of the most beneficial lifestyle
modifications for conditions seen frequently by primary care providers such as hypertension,
diabetes mellitus, cerebrovascular disease, coronary artery disease, acute coronary syndrome,
and more. Abstaining from using tobacco products is universally recommended.

A major concern about the potential risks associated with e-cigarette usage is whether the
FDA is able to adequately monitor the production of these products. While the FDA has recently
extended its tobacco regulatory power to include e-cigarettes as of 2016, the research to guide
these policies is currently limited1. A detailed description of the FDA’s current regulations can
be viewed below in Table 1. Due to the current nationwide outbreak of respiratory disease
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associated with e-cigarette usage, the CDC has advised the public to avoid e-cigarettes while
under investigation by federal and state officials4. As part of their investigations, state health
officials have sent samples of products to the FDA for analysis for THC and other cannabinoids,
nicotine, vitamin E acetate, along with cutting agents/diluents and other additives, pesticides,
opioids, poisons, heavy metals, and toxins4,6. According to the FDA, many of the recent cases
have involved a gradual start of symptoms including dyspnea on exertion, shortness of breath,
and/or chest pain before hospitalization. However, it is not clear if they have a common cause or
if they involve different diseases with similar presentations, and more information is needed to
determine what is causing the respiratory illness6. The ramifications that this research has for
society are quite substantial considering that more than 3.6 million middle and high school
students currently use e-cigarettes,4 and
15% of U.S. adults in 2014 reporting
trying an e-cigarette8.

The CDC recommendations
state that “adults who used e-cigarettes
containing nicotine to quit cigarette
smoking” should not return to smoking
conventional cigarettes, but they
provide no specific recommendations about refraining from e-cigarette use for these patients5.
The FDA only recommends seeking medical attention with suspected e-cigarette induced lung
disease, along with provider reporting of these incidences6. Without clear-cut recommendations
from the FDA and CDC, providers are forced to decide between the lesser of two evils. With the
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lack of long term research and data analysis, do you recommend staying away from e-cigarettes,
or does the overall benefit of reducing conventional cigarette use outweigh the unknown,
potentially detrimental effects of e-cigarette usage? While the idea of reducing tobacco usage by
any means possible remains the goal for most providers, supporters of e-cigarette use as a
healthier alternative to conventional cigarette smoking are promoting the benefits of this
cessation technique without evidence to support their claims and inadvertently putting the lives
of their patients at risk.

The purpose of this paper is to explore current research that quantifiably measures the
effect of e-cigarettes on pulmonary function. The major type of PFTs include spirometry,
spirometry before and after a bronchodilator, lung volumes, and quantitation of diffusing
capacity for carbon monoxide9. Spirometry is the most useful and readily available pulmonary
function test, only takes 10 to 15 minutes to complete, and carries minimal risk9. It is important
in the evaluation of chronic cough and airflow obstruction and used to diagnose and monitor a
broad spectrum of respiratory diseases including asthma, COPD, interstitial lung disease, and
neuromuscular diseases affecting respiratory muscles9.

Spirometry is performed by measuring the volume of air exhaled at specific time points
during a forceful and complete exhalation after a maximal inhalation9. The most important
variables gained from PFTs are the total exhaled volume (FVC), the volume forcibly exhaled in
one second (FEV1), and the ratio of these values (FEV1/FVC)9. An obstructive disease pattern is
indicated by a low FEV1/FVC ratio, which is defined as less than 70% of expected or below the
fifth percentile in adults, and less than 85% in patients between 5 and 18 years of age10. A
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restrictive disease pattern is indicated by an FVC below the fifth percentile in adults, or less than
80% in patients between 5 to 18 years of age10.

Case
S.C. is a 65 year old male with a 40 pack year smoking history who recently was advised
by his primary care provider on the health benefits of smoking cessation. He is worried about his
health, but no matter what method he tries, he is unable to quit smoking. He is interested in the
possibility of replacing his conventional cigarettes with e-cigarettes because he hears he can
control the amount of nicotine he is getting. However, he has seen a lot of negative media on ecigarettes lately and is wondering if they would actually be safer for him to use than traditional
cigarettes. Should the recommendation be made for him to switch to e-cigarettes?

Clinical Question
Among healthy adult smokers, does e-cigarette smoking as compared to traditional
cigarette smoking improve pulmonary function tests?
Table 2. PICO Framework Table

PICO Framework Table
P

Population

Healthy Adult Smokers

I

Intervention

E-cigarette smoking

C

Comparison

Conventional cigarette smoking

O

Outcome

Improvement in Pulmonary Function Tests (FEVI, FVC)

Methods
Initially, in September of 2019, a PubMed search was performed using the MeSH terms
“electronic nicotine delivery systems” or “vaping,” and “respiratory function tests,” and a Scopus
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search was performed using the terms “respiratory function test,” “electronic cigarette,” and
“short-term.” Search results yielded a total of 18 articles, which were then further stratified to
exclude articles with non-human species (3 articles), non-healthy subjects (4 articles), review
articles (2 articles), and non-smokers (5 articles). Of the 4 articles remaining, one article was
excluded for being a single subject case study, leaving a total of 3 articles to be used for
quantitative meta-analysis. The PRISMA flow chart used is located in Figure 1.

Figure 1. PRISMA Flow Diagram.
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Results
Study #1
Measurement of Cardiovascular and Pulmonary Function Endpoints and other Physiological
Effects Following Partial or Complete Substitution of Cigarettes with Electronic Cigarettes in
Adult Smokers. D’Ruiz et al.

Study Objective
To evaluate acute changes in select physiological parameters associated with
cardiovascular physiology (systolic and diastolic BP and HR), pulmonary function (FVC, FEV1,
and exhaled CO and NO), and adverse events among groups that either completely or partially
switched from conventional cigarettes to e-cigarettes or completely discontinued using tobacco
and nicotine products altogether11.

Study Design
One hundred and five (105) subjects meeting the eligibility criteria were enrolled into the
study and randomized into one of six study groups described below in Table 3. The main criteria
for inclusion and exclusion in the study are described below in Table 4. This was a randomized,
open-label, forced-switch parallel arm study conducted at a single independent research center
(Celerion, Lincoln, NE)11. Baseline assessments occurred on the morning of day one prior to the
start of randomized product use and post-baseline assessments were performed in the morning on
days one through six11.
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Table 3. Study #1 Study Groups11.

Exclusive E-Cigarette Use Groups
Group A1

Tobacco flavor rechargeable bluTM e-cigarette

Group A2

Cherry flavor rechargeable bluTM e-cigarette

Group A3

Cherry flavor disposable bluTM e-cigarette

Dual Use Groups
Group B1

Tobacco flavor rechargeable bluTM e-cigarette + usual brand combustible
tobacco cigarette

Group B2

Cherry flavor disposable bluTM e-cigarette + usual brand combustible
tobacco cigarette

Group B3

Cherry flavor disposable bluTM e-cigarette + usual brand combustible
tobacco cigarette

Cessation Group
Group C

Complete tobacco and nicotine product cessation

Table 4. Study #1 - Inclusion and Exclusion Criteria11.

Inclusion Criteria
● Healthy adult male and female smokers
● 21-65 years of age
● A smoker for at least 12 months
● Currently smoked an average of 10 or
more conventional manufactured
tobacco cigarettes per day (any brand,
any style)
● Consistent use of their current usual
brand style for 14 days prior to check in
● Positive urine cotinine at screening
(≤ 500 ng/mL)
● Exhaled carbon monoxide >12 ppm at
screening.

Exclusion Criteria
● History or presence of clinically significant
mental or physical health conditions
● Females who were pregnant or breastfeeding
● High blood pressure
● Body mass index < 18 kg/m2 or > 40 kg/m2
● Acute respiratory illnesses requiring
treatment within 2 weeks prior to check-in
● Use of prescription smoking cessation
treatments
● Anti-diabetic or insulin drugs or
medications
● Positive urine screen for alcohol or drugs
of abuse
● Self-reported mouth-hold smokers
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Use of tobacco or nicotine-containing e-cigarette products was only permitted per the
study protocol and randomization during the entire duration of the study, and was documented
daily by clinic staff11. Subjects in the cessation group were housed in an area of the clinic
separate from other groups to minimize the chance for illicit product use and crosscontamination11. With few exceptions, all product use was ad libitum from 07:30 to 23:00 on
days 2-511. The exceptions were meals and questionnaire administration, 15 minutes prior to
blood sampling and vital sign measurements, and 30 minutes prior to and during spirometry and
exhaled CO and NO measurements11.

Subjects randomized to receive the e-cigarette products were trained on how to use the ecigarettes upon check-in and then again on day 111. New e-cigarettes were supplied to the
subjects each morning and throughout the day if the e-liquid solution was fully consumed, and
all e-cigarettes were weighed before and after use. Subjects in the dual use group were required
to reduce their daily cigarette consumption on days 1-5 by ~50% of that reported at baseline11.
To assess how much nicotine was being delivered to the subjects, a rough estimate of the
maximum amount of nicotine possibly delivered from each e-cigarette was calculated using the
following simple mass-balance calculation: Estimated Nicotine Delivery (mg) = Pre-weight Post-weight difference (mg) nicotine strength (%)11. Product use data was listed by subject and
day and was summarized by subject, product use group, and day using descriptive statistics
(arithmetic mean, standard deviation, coefficient of variation, sample size, minimum, maximum,
and median)11. A paired t-test was used to make within-group cohort comparisons of the daily
estimated amount of nicotine delivered by the e-cigarettes and the number of cigarettes smoked
per day11.
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Spirometry measures of the volume of air exhaled during a forced breath in one second
(FEV1) and total volume of air exhaled (FVC) were measured by the study physician or
appropriate clinical staff in subjects to assess any impacts of product use on lung function11. Both
baseline (day 1) and post-baseline (day 5) changes in FVC and FEV1 spirometry endpoints were
performed in the afternoon using a KoKo® Spirometer and methods consistent with American
Thoracic Society guidelines11. FVC and FEV1 values were documented and descriptive
statistics, including a measured value summary and measured value percentage change from
baseline was provided for all data11. A paired t-test was used to make within-group comparisons
and a linear mixed model was used to compare between-group differences in FVC and FEV111.

Statistical analyses were performed using SAS procedures in SAS® Version 9.311. A
paired t-test was used to make within-group comparisons between study days and a linear mixed
model was used to assess between-group differences11. Baseline values were included in the
statistical models for the between-group comparisons as a covariate11. Differences were
considered statistically significant at an alpha level of 5% (p < 0.05).

Study Results
The measured FVC summary and statistical comparisons can be viewed in Tables 5 and 6
below. The only statistically significant data occurred in the exclusive e-cigarette use groups in
those using the Tobacco Rechargeable (p-value of 0.0207) and Cherry Rechargeable e-cigarettes
(p-value of 0.0113), meaning the difference from the day 1 baseline measurement and the day 5
measurement in terms of FVC was significant in these groups11. The measured FEV1 summary
and statistical comparisons can be viewed in Tables 7 and 8 below. The only statistically
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significant data occurred in the Tobacco Rechargeable (p-value 0.0148) and Cherry
Rechargeable users (p-value 0.0276) within the exclusive e-cigarette use group, as well as the
Cherry Rechargeable users within the Dual Use Group (p-value 0.0191); meaning the difference
in FEV1 between the day 1 baseline and day 5 measurements, was statistically significant in
these groups11.

In summary, the use of e-cigarettes for five days under the various study conditions did
not lead to negative respiratory health outcomes11. The pulmonary function test results showed
small, but non-statistically significant improvements in FEV1 and FVC is most user groups11.
The most consistent statistically significant results occurred within the exclusive e-cigarette use
group in those using either of the two rechargeable e-cigarettes.

Figure 2. Summary of FVC and FEV1 Changes from Baseline by Use Group from Baseline to Day 511.
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Table 5. Measured FVC Summary and Day 5 vs. Baseline Statistical Comparisons11.

Table 6. Measured FEV1 Summary and Day 5 vs. Baseline Statistical Comparisons11.

Study Critique
The main limitation of this study is that it was only a short-term 5-day trial, and therefore
the results gained from it are difficult to translate into long term recommendations for patients
looking for another option besides conventional cigarettes. Therefore, longer-term studies may
be more appropriate for measuring the outcomes and physiological parameters associated with ecigarette product use. This study also only used one product type, namely the closed system ecigarettes11, making it difficult to make broad conclusions on all e-cigarettes as a whole. Lastly,
because the participants were housed at the research center throughout the duration of the study,
this may have motivated them to behave differently than they would in their regular daily lives,
which could have potentially affected the results of the study. However, this may be offset by the
fact that closer monitoring of patients allowed for better control of study variables that would not
have otherwise been possible.
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Study #2
Short-term Pulmonary Effects of Using an Electronic Cigarette - Impact on Respiratory Flow
Resistance, Impedance, and Exhaled Nitric Oxide. Vardavas et al.

Objective
To assess whether or not smoking an e-cigarette for 5 minutes has an effect on the
pulmonary function tests (FEV1, FVC, FEV1%, PEF, maximal expiratory flow at 25%, 50%, and
75%, and maximal mid-expiratory flow) in healthy smokers12.

Study Design
Thirty (30) adults, both male and female (14 men, 16 women), from Athens, Greece were
enrolled in this study based on whether or not they met the inclusion and exclusion criteria
provided in Table 5 below12. The e-cigarettes used during this study were all NOBACCO ecigarettes, black line, and all contained the same amount of nicotine, 11 mg, reported by the
manufacturer12.
Researchers implemented a laboratory-based intervention study design12. Participants
were told to withhold from eating and drinking for at least 2 hours and avoid smoking for 4 hours
prior to conduction of the study. All participants received baseline testing prior to the e-cigarette
trials. Ten participants were randomly selected to act as the control group during the first session.
During this session, both groups were asked to use an e-cigarette for 5 minutes as if normally
smoking. E-cigarettes given to the control group had the cartridges removed12. Doing so
prevented vapor production, therefore blinding was not possible. The experimental group was
given the same instructions but were provided e-cigarettes with the cartridge intact. Researchers
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then compared changes in pulmonary function between the experimental group (20 participants)
and the control group (10 participants)12. In the second session the same procedure was repeated
without a control group. Every subject participated as part of the experimental group (30 total
participants), smoking e-cigarettes with an intact cartridge, and researchers compared spirometry
findings of each individual to their own baseline pulmonary function.

Table 7. Study #2 - Inclusion and Exclusion Criteria12.

Inclusion Criteria
● Age 19-56 years old (average age
34.8)
● Minimum pack-year index of 5
● Current smokers at the time study was
conducted

Exclusion Criteria
● Chronic disease
● Lung disease (including history of
bronchial asthma or bronchial
hyperreactivity)
● Acute illness in the 2 weeks prior to
the study
● Currently pregnant or lactating
● Current use of any medications

Pulmonary function was measured via guidelines set by the American Thoracic
Society/European Respiratory Society task force guidelines using a Jaeger MasterScreen
spirometry system12. They measured FEV1, FVC, FEV1%, PEF, maximal expiratory flow at
25%, 50%, and 75% of vital capacity, and maximal mid-expiratory flow while the participants
were in a seated position12. Each test was repeated at least three times and all measurements
needed to be within 10% of the standard deviation after three attempts in order to meet the
criteria set for the study12. These criteria were put in place to ensure that subjects had received
proper instruction about how to use the equipment and allow them time to practice to feel
comfortable using the spirometer, in hopes to obtain a more accurate reading12.
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The authors of this study implemented the Kolmogorov-Smirnov tests for statistical
analysis of their data, and assessed the differences between pre- and post-measurements,
response based on gender, and experimental and control conditions using bivariate analysis12.
They report using the paired Student t test for parametric data and the Wilcoxon signed rank test
for nonparametric data12. The correlation between respiratory function tests prior to and after
intervention were analyzed by applying Pearson correlations12.

Study Results
Baseline spirometry results are listed in Table 6 below. No change in PFTs measured
using spirometry was noted after 5 minutes of e-cigarette use.

Table 8. Baseline Characteristics and Respiratory Function of Study Participants by Sex12.

Characteristic

Female

Male

P Valuea

Number
Age, y, mean ±SD

16
36 ±11

14
33 ±11

0.473

5.45
4.33
1.84
5.08
8.35
5.45
4.10

0.001
0.001
0.001
0.293
0.050
0.001
0.056

Spirometry
FVC, L
FEV1, L
PEF, L/s
MEF25, L/s
MEF50, L/s
MEF75, L/s
MMEF, L/s

3.64
3.02
1.50
3.93
6.04
3.64
3.16

MEF - maximal expiratory flow, MEF25 - maximal expiratory flow at 25% of vital capacity, MEF50 maximal expiratory flow at 50% of vital capacity, MEF75 - maximal expiratory flow at 75% of vital
capacity, MMEF - maximal mid-expiratory flow, PEF - peak expiratory flow, FVC - forced vital capacity,
FEV1 - forced expiratory volume in 1 s
a
“P Values based on Student t tests for all... performed with Wilcoxon signed rank test. P < 0.05 classified
as statistically significant.”
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Overall, researchers concluded that using an e-cigarette for as little as 5 minutes resulted
in physiologic responses, such as increased lung flow resistance, based on impulse
oscillometry12. Since impulse oscillometry is known to “detect oncoming pathophysiologic
changes of the respiratory system before spirometry,” these changes were not reflected in
spirometry results12. Although changes to pulmonary flow resistance noted during the study were
too small to induce any clinically relevant symptoms in study participants, researchers claim that
the general public is at a higher risk of becoming symptomatic with increased regular use given
they smoke more than 5 minutes per day12.

Study Critique
Although this study did a good job of excluding individuals with chronic and/or lung
disease and other potential confounding, health-related variables, the authors of this study failed
to report spirometry data other than baseline measurements. Data and statistical analysis from
other measurements, such as impulse oscillometry, was performed and reported, but these
findings were not of interest in this meta-analysis. Without explicit data from this study, we were
unable to determine what the spirometry results showed and if they were statistically significant.
This forced us to analyze the results of this study based off of what we could infer from their
conclusion, deeming our analysis invalid due to insignificant data. Limitations, determined by
the authors of this study, have convinced researchers to recommend that more research be done
in order to support the claims they have made, determine more tangible evidence of adverse
health effects, and look into if the long term benefits of smoking cessation outweigh the short
term adverse effects of e-cigarette use12.
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Study #3
First Comparative Results About the Direct Effect of Traditional Cigarette and E-cigarette
Smoking on Lung Alveolocapillary Membrane Using Dynamic Ventilation Scintigraphy. Barna,
et al.

Objective
To compare Dynamic Inhalation Scintigraphy (DIS) results in healthy subjects with a
history of conventional cigarette smoking, after using an e-cigarette and after returning to
smoking conventional cigarettes for one week13.

Study Design
Twenty-four (24) healthy male subjects, with an average age of 35 years old, volunteered
to participate in this study. The inclusion and exclusion criteria set by researchers is present in
Table 7 below13. Each participant received baseline pulmonary function testing while using ecigarettes regularly13. Participants were then instructed to return to smoking conventional
cigarettes for one week, requiring them to smoke at least 20-25 cigarettes per day13. After one
week of conventional cigarette use, pulmonary function tests were performed for a second time
in all patients except one who was examined after 8 days of conventional cigarette use13. Data
from this individual was not included in their analysis. Respiration tests, measuring FVC, FEV1,
PEF, and FEV1/FVC, were performed using EuTest Plus VT-17 spirometry13.
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Statistical analysis, using the paired t-test, was done to compare differences between the
initial baseline pulmonary function with e-cigarette use and measurements after one week of
conventional cigarette use13.

Table 9. Study #3 - Inclusion and Exclusion Criteria13.

Inclusion Criteria

Exclusion Criteria

● Age ranging from 20-64 years old
● Heavy smokers in the past
● Regular use of e-cigarettes containing
≥ 10 mg nicotine/mL at the time of the
study

● Subjects with respiratory complaints
● Subjects with known pulmonary
disease

Study Results
Data collected from individual test subjects is located in Table 8, and the results of
statistical analysis are presented in Table 9. Data from this study showed statistically significant
decreases in FVC and FEV1 ( p < 0.05, paired t-test) after 1 week of traditional cigarette use, but
no significant differences in PEF and FEV1/FVC were found between cigarette and e-cigarette
use13. This study concluded that from their results, the harm associated with e-cigarette use is
less significant than that of conventional cigarettes13. They recommended e-cigarettes be used as
a tool to help patients who are heavy smokers quit smoking13.
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Table 10. Study #3 - Baseline with Regular E-cigarette Use vs. Conventional Cigarette Use 7 Days13.

Pulmonary
Function
Tests

e-cigarette > cigarette

e-cigarette < cigarette

e-cigarette = cigarette

Total

FVC

16

5

3

24

FEV1

2

22

0

24

# of Study Participants

Cigarette - Spirometry results after 7 days of conventional cigarette use
E-cigarette - Baseline spirometry results with regular e-cigarette use
FVC - forced vital capacity, FEV1 - forced expiratory volume in 1 sec

Table 11. Study #3 - Results of Statistical Comparison of Pulmonary Test Parameters13.
Paired Differences
Comparison:
ec to c

Mean

SD

SEM

95% CI of the
difference

t

d.f.

Significance
(two tailed)

FVC
0.13750 0.28135 0.05743
0.01870 - 0.25630
2.394 23
0.025
FEV1
0.15833 0.36406 0.07431
0.00461 - 0.31206
2.131 23
0.044
PEF
0.77750 1.91179 0.39024 - 0.02978 to 1.58478 1.992 23
0.058
FEV1/FVC
0.01000 0.03683 0.00752 - 0.00555 to 0.02555 1.330 23
0.197
Shapiro-Wilk test (P > 0.1) and paired t-test.
c - conventional cigarette, ec - e-cigarette, d.f - degrees of freedom, FVC - forced vital capacity, FEV1 forced expiratory volume in 1 s, PEF - peak expiratory flow rate

Study Critique
Limitations of this study include its size and researchers’ ability to control smoking
frequency, methods, and nicotine intake prior to and during the experiment. This study was too
small with a very limited number of participants all of whom were male, and the study groups
were not randomized or blinded.

All participants were considered to be “heavy smokers” requiring prior use of
conventional cigarettes in order to meet inclusion criteria. Determinants of what was considered
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to be heavy smoking, the frequency or duration of their conventional cigarette use, nor the
amount of time passed since participants stopped using conventional cigarettes was explicitly
stated by researchers. Considering the wide variety of ages, these parameters would have been
important in determining the homogeneity or heterogeneity of the study population being
studied.

Regular use of e-cigarettes containing at least 10 mg nicotine/mL at the time of the study
was also required to participate. The frequency and duration of “regular” e-cigarette use was
never defined. There was no maximum limit to the amount of nicotine allowed in e-cigarettes
used by study participants. They did not report the amount of nicotine in each individual’s ecigarette cartridge prior to the study.

During the study, participants were asked to return to conventional cigarette use for 1
week and were informed to smoke at least 20-25 cigarettes/day, but there was no maximum limit
to how many cigarettes they could smoke in a day, and the number of cigarettes smoked per day
by participants was not explicitly stated.

All of the following has lead us to believe that there could have been large variations in
pulmonary function between study participants. Researchers did not correct for these
confounding variables, affecting the validity of their results.
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Discussion
The first study was the largest and most well-designed study that was analyzed. It
involved over one-hundred adult male and female participants who had to satisfy strict inclusion
and exclusion criteria. Similarly, to much of the current literature on this topic, the main critique
of the study was that it was short-term, lasting only 5 days. Based on the results within this
study, there is a lack of statistically significant evidence to recommend that a patient make the
switch from a conventional to a traditional cigarette. The data that was significant informs us that
there might be a benefit to exclusive e-cigarette usage with either a rechargeable tobacco
flavored or rechargeable cherry flavored e-cigarette, however further long term studies are
needed in order to strengthen this data.

In the second study, researchers compared PFTs of experimental and control groups after
5 minutes of e-cigarette use, with the only difference between groups being the presence or
absence of the e-cigarette cartridge (respectively). They also measured the difference between
PFTs of current smokers before (baseline) and after 5 minutes of e-cigarette use. The results of
spirometry, both baseline and post-exposure, were deemed within normal limits. This, along with
other limitations of the study, is the reason data from this study cannot be applied to our patient
or be used for making clinical decisions regarding e-cigarettes.

The third study was the only study from our analysis to actually give recommendations
about the role of e-cigarettes as a smoking cessation technique. Researchers reported that “it can
be recommended to heavy smokers who are unable to stop smoking” since their research was
able to reveal statistically significant evidence of decreased FVC and FEV1 after smoking
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conventional cigarettes for a total of 7 days13. Although this data is the most recent from the
articles analyzed in the review the limitations of this study negate the validity of it’s statistically
significant data.

Out of all the studies reviewed, the third one had the least amount of criteria for
participants entering into the study. The study only included subjects of male gender, had a very
small sample size used in statistical analysis (23 subjects), did not account for confounding
variables that could have affected lung function and adaptability prior to participation, and were
unable to limit the amount of cigarettes smoked amongst study participants during the
experiment which in turn impaired their ability to provide equivocal amounts of e-cigarette and
conventional cigarette use for comparison. All of which could have led to the results they found.

Of importance was the lack of a maximum limit for cigarette and e-cigarette use present
in any of the studies reviewed. All set minimum amounts for participants to comply with, but
without a maximum limit it can be suspected, especially with the wide age ranges consistent
between studies, that some participants with a history of increased duration/frequency of
cigarette use were predisposed to alterations in lung function due to an inability of their lungs to
adapt to physiologic changes caused by cigarette or e-cigarette use.

The differences between the chosen studies due to the lack of available literature on this
topic currently, created a weakness in our meta-analysis itself as well. Most notably, while each
of our studies included measurements of pulmonary function testing (FEV1, FVC) in healthy
adult smokers, they each had very different study designs. The first study specifically tried to
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look at the differences in physiologic parameters in those who either partly switched to ecigarettes, fully switched to e-cigarettes, or gave up tobacco products entirely, while the second
study looked at differences between those using e-cigarettes with and without a cartridge, and the
third study observed changes seen after one week of conventional cigarette use in prior ecigarette users. The lack of congruence seen in the current data reflects our need for further
evaluation on this topic.

Conclusion
Two out of the three studies that were analyzed did not yield statistically significant
results able to be utilized in formal recommendations for patients. The main obstacle that these
studies faced was that they were short term, measuring physiologic changes either over a 5 day,
or a 5 minute period. The third and final study was able to come to the conclusion that e-cigarette
usage is safer than conventional cigarettes and should be offered to patients as a safer alternative.
However, this study had the most flaws out of all three, making this conclusion a weak one at
best. Specifically, this study had the smallest sample size, with only 23 subjects included in the
data analysis, included only male subjects, and had very few parameters the amount of ecigarette usage throughout the study.
Before a formal recommendation can be made to S.C. on whether he should switch from
conventional cigarettes to e-cigarettes, more long-term, well designed studies need to be
performed. At this time, we recommend that S.C be shown the current evidence in support of ecigarettes, while also being warned about possible untoward side effects and making sure he is
well informed on the current cases of vaping related deaths so that he can make an educated
decision.
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